COMPARISON OF PROTECTIVE EFFECT OF NEUTRALIZING ANTIBODY IN SERUM AND NASAL SECRETIONS IN EXPERIMENTAL RHINOVIRUS TYPE 13 ILLNESS
Perkins, J. C. (NIAID, NIH, Bethesda, Md. 20014), D. N. Tucker, H.L.S. Knopf, R. P. Wenzel, A. Z. Kapikian and R. M. Chanock. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Amer. J. Epid., 1969, 90: 519–526.—An inact...
Gespeichert in:
| Veröffentlicht in: | American journal of epidemiology 1969-12, Vol.90 (6), p.519-526 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 526 |
|---|---|
| container_issue | 6 |
| container_start_page | 519 |
| container_title | American journal of epidemiology |
| container_volume | 90 |
| creator | PERKINS, JOHN C. TUCKER, DAVID N. KNOPF, HARRY L. S. WENZEL, RICHARD P. KAPIKIAN, ALBERT Z. CHANOCK, ROBERT M. |
| description | Perkins, J. C. (NIAID, NIH, Bethesda, Md. 20014), D. N. Tucker, H.L.S. Knopf, R. P. Wenzel, A. Z. Kapikian and R. M. Chanock. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Amer. J. Epid., 1969, 90: 519–526.—An inactivated rhinovirus type 13 vaccine was administered to adult male volunteers by the intramuscular (IM) or intranasal (IN) route. When the men were challenged with approximately 100 TCD50 of type 13 virus, a significant protective effect was seen in individuals given vaccine IN, whereas the frequency with which illness developed in IM vaccinees did not differ from that of the seronegative controls. The volunteers who received the vaccine IN developed both serum and nasal secretory antibodies, while the volunteers who were vaccinated IM developed primarily a serum antibody response. When the response to challenge of the vaccinees was evaluated according to level of serum or nasal antibody, only nasal secretory antibody was associated with resistance to infection and illness. |
| doi_str_mv | 10.1093/oxfordjournals.aje.a121098 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_84347134</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1306646821</sourcerecordid><originalsourceid>FETCH-LOGICAL-i187t-172c89ccf4c0cd2860dda454d09ea7addaf63302b1bdb324b6789412a2731a103</originalsourceid><addsrcrecordid>eNpdkF9r2zAUxcXY6LJuH2EgNtibM11JkexH11EagSMb2yltX4T8J5AsqTs7ge6x37wqzfawp3vP-R0u3IPQNyBTIBH72T9t-qHd9afhwe3Hqdt1UwfUo_AdmgCXIhB0Jt6jCSGEBhEV9CP6NI47QgCiGblAF5wBJUJM0HOSrfK40GVmcLbAeZFVKqn0jcJqsfDbq2nUuiriVN9rc41jU-mrbH6HtcGlKtYr78yxics49TopVKUzU75SdZurQq-UqTwqltpkN7pYl7i6yxUGhnWaGlWWn9GHjf-i-3Kel2i9UFWyDNLsWidxGmwhlMcAJG3CqGk2vCFNS0NB2tbxGW9J1DnpvNgIxgitoW5rRnktZBhxoI5KBg4Iu0Q_3u4-Dv3vUzce7WE7Nt1-7x66_jTakDMugXEf_P5f8G_TFpgvjYuQgk99PadO9aFr7eOwPbjhjz0363nwxrfjsXv6h93wywrJ5Mwub-8ti67mS5rMbc5eAOr2g9o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1306646821</pqid></control><display><type>article</type><title>COMPARISON OF PROTECTIVE EFFECT OF NEUTRALIZING ANTIBODY IN SERUM AND NASAL SECRETIONS IN EXPERIMENTAL RHINOVIRUS TYPE 13 ILLNESS</title><source>MEDLINE</source><source>Oxford University Press Journals Digital Archive Legacy</source><source>Periodicals Index Online</source><creator>PERKINS, JOHN C. ; TUCKER, DAVID N. ; KNOPF, HARRY L. S. ; WENZEL, RICHARD P. ; KAPIKIAN, ALBERT Z. ; CHANOCK, ROBERT M.</creator><creatorcontrib>PERKINS, JOHN C. ; TUCKER, DAVID N. ; KNOPF, HARRY L. S. ; WENZEL, RICHARD P. ; KAPIKIAN, ALBERT Z. ; CHANOCK, ROBERT M.</creatorcontrib><description>Perkins, J. C. (NIAID, NIH, Bethesda, Md. 20014), D. N. Tucker, H.L.S. Knopf, R. P. Wenzel, A. Z. Kapikian and R. M. Chanock. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Amer. J. Epid., 1969, 90: 519–526.—An inactivated rhinovirus type 13 vaccine was administered to adult male volunteers by the intramuscular (IM) or intranasal (IN) route. When the men were challenged with approximately 100 TCD50 of type 13 virus, a significant protective effect was seen in individuals given vaccine IN, whereas the frequency with which illness developed in IM vaccinees did not differ from that of the seronegative controls. The volunteers who received the vaccine IN developed both serum and nasal secretory antibodies, while the volunteers who were vaccinated IM developed primarily a serum antibody response. When the response to challenge of the vaccinees was evaluated according to level of serum or nasal antibody, only nasal secretory antibody was associated with resistance to infection and illness.</description><identifier>ISSN: 0002-9262</identifier><identifier>EISSN: 1476-6256</identifier><identifier>DOI: 10.1093/oxfordjournals.aje.a121098</identifier><identifier>PMID: 4312066</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>active ; Adult ; antibodies ; Antibodies - analysis ; Antigens - analysis ; Common Cold - immunology ; Common Cold - prevention & control ; Humans ; immunity ; immunization ; Injections, Intramuscular ; Male ; Middle Aged ; Nasal Mucosa - metabolism ; Neutralization Tests ; rhinovirus ; Rhinovirus - pathogenicity ; Vaccination ; viral vaccines ; Viral Vaccines - abnormalities ; virology ; virus diseases</subject><ispartof>American journal of epidemiology, 1969-12, Vol.90 (6), p.519-526</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27869,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4312066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PERKINS, JOHN C.</creatorcontrib><creatorcontrib>TUCKER, DAVID N.</creatorcontrib><creatorcontrib>KNOPF, HARRY L. S.</creatorcontrib><creatorcontrib>WENZEL, RICHARD P.</creatorcontrib><creatorcontrib>KAPIKIAN, ALBERT Z.</creatorcontrib><creatorcontrib>CHANOCK, ROBERT M.</creatorcontrib><title>COMPARISON OF PROTECTIVE EFFECT OF NEUTRALIZING ANTIBODY IN SERUM AND NASAL SECRETIONS IN EXPERIMENTAL RHINOVIRUS TYPE 13 ILLNESS</title><title>American journal of epidemiology</title><addtitle>Am J Epidemiol</addtitle><description>Perkins, J. C. (NIAID, NIH, Bethesda, Md. 20014), D. N. Tucker, H.L.S. Knopf, R. P. Wenzel, A. Z. Kapikian and R. M. Chanock. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Amer. J. Epid., 1969, 90: 519–526.—An inactivated rhinovirus type 13 vaccine was administered to adult male volunteers by the intramuscular (IM) or intranasal (IN) route. When the men were challenged with approximately 100 TCD50 of type 13 virus, a significant protective effect was seen in individuals given vaccine IN, whereas the frequency with which illness developed in IM vaccinees did not differ from that of the seronegative controls. The volunteers who received the vaccine IN developed both serum and nasal secretory antibodies, while the volunteers who were vaccinated IM developed primarily a serum antibody response. When the response to challenge of the vaccinees was evaluated according to level of serum or nasal antibody, only nasal secretory antibody was associated with resistance to infection and illness.</description><subject>active</subject><subject>Adult</subject><subject>antibodies</subject><subject>Antibodies - analysis</subject><subject>Antigens - analysis</subject><subject>Common Cold - immunology</subject><subject>Common Cold - prevention & control</subject><subject>Humans</subject><subject>immunity</subject><subject>immunization</subject><subject>Injections, Intramuscular</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nasal Mucosa - metabolism</subject><subject>Neutralization Tests</subject><subject>rhinovirus</subject><subject>Rhinovirus - pathogenicity</subject><subject>Vaccination</subject><subject>viral vaccines</subject><subject>Viral Vaccines - abnormalities</subject><subject>virology</subject><subject>virus diseases</subject><issn>0002-9262</issn><issn>1476-6256</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1969</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>K30</sourceid><recordid>eNpdkF9r2zAUxcXY6LJuH2EgNtibM11JkexH11EagSMb2yltX4T8J5AsqTs7ge6x37wqzfawp3vP-R0u3IPQNyBTIBH72T9t-qHd9afhwe3Hqdt1UwfUo_AdmgCXIhB0Jt6jCSGEBhEV9CP6NI47QgCiGblAF5wBJUJM0HOSrfK40GVmcLbAeZFVKqn0jcJqsfDbq2nUuiriVN9rc41jU-mrbH6HtcGlKtYr78yxics49TopVKUzU75SdZurQq-UqTwqltpkN7pYl7i6yxUGhnWaGlWWn9GHjf-i-3Kel2i9UFWyDNLsWidxGmwhlMcAJG3CqGk2vCFNS0NB2tbxGW9J1DnpvNgIxgitoW5rRnktZBhxoI5KBg4Iu0Q_3u4-Dv3vUzce7WE7Nt1-7x66_jTakDMugXEf_P5f8G_TFpgvjYuQgk99PadO9aFr7eOwPbjhjz0363nwxrfjsXv6h93wywrJ5Mwub-8ti67mS5rMbc5eAOr2g9o</recordid><startdate>196912</startdate><enddate>196912</enddate><creator>PERKINS, JOHN C.</creator><creator>TUCKER, DAVID N.</creator><creator>KNOPF, HARRY L. S.</creator><creator>WENZEL, RICHARD P.</creator><creator>KAPIKIAN, ALBERT Z.</creator><creator>CHANOCK, ROBERT M.</creator><general>Oxford University Press</general><general>School of Hygiene and Public Health of the Johns Hopkins University</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>HVZBN</scope><scope>K30</scope><scope>PAAUG</scope><scope>PAWHS</scope><scope>PAWZZ</scope><scope>PAXOH</scope><scope>PBHAV</scope><scope>PBQSW</scope><scope>PBYQZ</scope><scope>PCIWU</scope><scope>PCMID</scope><scope>PCZJX</scope><scope>PDGRG</scope><scope>PDWWI</scope><scope>PETMR</scope><scope>PFVGT</scope><scope>PGXDX</scope><scope>PIHIL</scope><scope>PISVA</scope><scope>PJCTQ</scope><scope>PJTMS</scope><scope>PLCHJ</scope><scope>PMHAD</scope><scope>PNQDJ</scope><scope>POUND</scope><scope>PPLAD</scope><scope>PQAPC</scope><scope>PQCAN</scope><scope>PQCMW</scope><scope>PQEME</scope><scope>PQHKH</scope><scope>PQMID</scope><scope>PQNCT</scope><scope>PQNET</scope><scope>PQSCT</scope><scope>PQSET</scope><scope>PSVJG</scope><scope>PVMQY</scope><scope>PZGFC</scope><scope>7X8</scope></search><sort><creationdate>196912</creationdate><title>COMPARISON OF PROTECTIVE EFFECT OF NEUTRALIZING ANTIBODY IN SERUM AND NASAL SECRETIONS IN EXPERIMENTAL RHINOVIRUS TYPE 13 ILLNESS</title><author>PERKINS, JOHN C. ; TUCKER, DAVID N. ; KNOPF, HARRY L. S. ; WENZEL, RICHARD P. ; KAPIKIAN, ALBERT Z. ; CHANOCK, ROBERT M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i187t-172c89ccf4c0cd2860dda454d09ea7addaf63302b1bdb324b6789412a2731a103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1969</creationdate><topic>active</topic><topic>Adult</topic><topic>antibodies</topic><topic>Antibodies - analysis</topic><topic>Antigens - analysis</topic><topic>Common Cold - immunology</topic><topic>Common Cold - prevention & control</topic><topic>Humans</topic><topic>immunity</topic><topic>immunization</topic><topic>Injections, Intramuscular</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nasal Mucosa - metabolism</topic><topic>Neutralization Tests</topic><topic>rhinovirus</topic><topic>Rhinovirus - pathogenicity</topic><topic>Vaccination</topic><topic>viral vaccines</topic><topic>Viral Vaccines - abnormalities</topic><topic>virology</topic><topic>virus diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PERKINS, JOHN C.</creatorcontrib><creatorcontrib>TUCKER, DAVID N.</creatorcontrib><creatorcontrib>KNOPF, HARRY L. S.</creatorcontrib><creatorcontrib>WENZEL, RICHARD P.</creatorcontrib><creatorcontrib>KAPIKIAN, ALBERT Z.</creatorcontrib><creatorcontrib>CHANOCK, ROBERT M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Periodicals Index Online Segment 24</collection><collection>Periodicals Index Online</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - West</collection><collection>Primary Sources Access (Plan D) - International</collection><collection>Primary Sources Access & Build (Plan A) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Midwest</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Northeast</collection><collection>Primary Sources Access (Plan D) - Southeast</collection><collection>Primary Sources Access (Plan D) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Southeast</collection><collection>Primary Sources Access (Plan D) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - UK / I</collection><collection>Primary Sources Access (Plan D) - Canada</collection><collection>Primary Sources Access (Plan D) - EMEALA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - North Central</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - International</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - International</collection><collection>Primary Sources Access (Plan D) - West</collection><collection>Periodicals Index Online Segments 1-50</collection><collection>Primary Sources Access (Plan D) - APAC</collection><collection>Primary Sources Access (Plan D) - Midwest</collection><collection>Primary Sources Access (Plan D) - MEA</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - Canada</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - EMEALA</collection><collection>Primary Sources Access & Build (Plan A) - APAC</collection><collection>Primary Sources Access & Build (Plan A) - Canada</collection><collection>Primary Sources Access & Build (Plan A) - West</collection><collection>Primary Sources Access & Build (Plan A) - EMEALA</collection><collection>Primary Sources Access (Plan D) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - Midwest</collection><collection>Primary Sources Access & Build (Plan A) - North Central</collection><collection>Primary Sources Access & Build (Plan A) - Northeast</collection><collection>Primary Sources Access & Build (Plan A) - South Central</collection><collection>Primary Sources Access & Build (Plan A) - Southeast</collection><collection>Primary Sources Access (Plan D) - UK / I</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - APAC</collection><collection>Primary Sources Access—Foundation Edition (Plan E) - MEA</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PERKINS, JOHN C.</au><au>TUCKER, DAVID N.</au><au>KNOPF, HARRY L. S.</au><au>WENZEL, RICHARD P.</au><au>KAPIKIAN, ALBERT Z.</au><au>CHANOCK, ROBERT M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COMPARISON OF PROTECTIVE EFFECT OF NEUTRALIZING ANTIBODY IN SERUM AND NASAL SECRETIONS IN EXPERIMENTAL RHINOVIRUS TYPE 13 ILLNESS</atitle><jtitle>American journal of epidemiology</jtitle><addtitle>Am J Epidemiol</addtitle><date>1969-12</date><risdate>1969</risdate><volume>90</volume><issue>6</issue><spage>519</spage><epage>526</epage><pages>519-526</pages><issn>0002-9262</issn><eissn>1476-6256</eissn><abstract>Perkins, J. C. (NIAID, NIH, Bethesda, Md. 20014), D. N. Tucker, H.L.S. Knopf, R. P. Wenzel, A. Z. Kapikian and R. M. Chanock. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Amer. J. Epid., 1969, 90: 519–526.—An inactivated rhinovirus type 13 vaccine was administered to adult male volunteers by the intramuscular (IM) or intranasal (IN) route. When the men were challenged with approximately 100 TCD50 of type 13 virus, a significant protective effect was seen in individuals given vaccine IN, whereas the frequency with which illness developed in IM vaccinees did not differ from that of the seronegative controls. The volunteers who received the vaccine IN developed both serum and nasal secretory antibodies, while the volunteers who were vaccinated IM developed primarily a serum antibody response. When the response to challenge of the vaccinees was evaluated according to level of serum or nasal antibody, only nasal secretory antibody was associated with resistance to infection and illness.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>4312066</pmid><doi>10.1093/oxfordjournals.aje.a121098</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9262 |
| ispartof | American journal of epidemiology, 1969-12, Vol.90 (6), p.519-526 |
| issn | 0002-9262 1476-6256 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_84347134 |
| source | MEDLINE; Oxford University Press Journals Digital Archive Legacy; Periodicals Index Online |
| subjects | active Adult antibodies Antibodies - analysis Antigens - analysis Common Cold - immunology Common Cold - prevention & control Humans immunity immunization Injections, Intramuscular Male Middle Aged Nasal Mucosa - metabolism Neutralization Tests rhinovirus Rhinovirus - pathogenicity Vaccination viral vaccines Viral Vaccines - abnormalities virology virus diseases |
| title | COMPARISON OF PROTECTIVE EFFECT OF NEUTRALIZING ANTIBODY IN SERUM AND NASAL SECRETIONS IN EXPERIMENTAL RHINOVIRUS TYPE 13 ILLNESS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T07%3A13%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COMPARISON%20OF%20PROTECTIVE%20EFFECT%20OF%20NEUTRALIZING%20ANTIBODY%20IN%20SERUM%20AND%20NASAL%20SECRETIONS%20IN%20EXPERIMENTAL%20RHINOVIRUS%20TYPE%2013%20ILLNESS&rft.jtitle=American%20journal%20of%20epidemiology&rft.au=PERKINS,%20JOHN%20C.&rft.date=1969-12&rft.volume=90&rft.issue=6&rft.spage=519&rft.epage=526&rft.pages=519-526&rft.issn=0002-9262&rft.eissn=1476-6256&rft_id=info:doi/10.1093/oxfordjournals.aje.a121098&rft_dat=%3Cproquest_pubme%3E1306646821%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1306646821&rft_id=info:pmid/4312066&rfr_iscdi=true |